AU2012240110B2 - Method for the generation of compact tale-nucleases and uses thereof - Google Patents

Method for the generation of compact tale-nucleases and uses thereof Download PDF

Info

Publication number
AU2012240110B2
AU2012240110B2 AU2012240110A AU2012240110A AU2012240110B2 AU 2012240110 B2 AU2012240110 B2 AU 2012240110B2 AU 2012240110 A AU2012240110 A AU 2012240110A AU 2012240110 A AU2012240110 A AU 2012240110A AU 2012240110 B2 AU2012240110 B2 AU 2012240110B2
Authority
AU
Australia
Prior art keywords
dna
compact talen
domain
seq
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012240110A
Other languages
English (en)
Other versions
AU2012240110A1 (en
Inventor
Claudia BERTONATI
Philippe Duchateau
Jean-Charles Epinat
Alexandre Juillerat
George H. Silva
Julien Valton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis SA filed Critical Cellectis SA
Publication of AU2012240110A1 publication Critical patent/AU2012240110A1/en
Application granted granted Critical
Publication of AU2012240110B2 publication Critical patent/AU2012240110B2/en
Priority to AU2017248447A priority Critical patent/AU2017248447B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012240110A 2011-04-05 2012-04-05 Method for the generation of compact tale-nucleases and uses thereof Active AU2012240110B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017248447A AU2017248447B2 (en) 2011-04-05 2017-10-17 Method for the generation of compact tale-nucleases and uses thereof

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201161472065P 2011-04-05 2011-04-05
US61/472,065 2011-04-05
US201161496454P 2011-06-13 2011-06-13
US61/496,454 2011-06-13
US201161499047P 2011-06-20 2011-06-20
US201161499043P 2011-06-20 2011-06-20
US61/499,043 2011-06-20
US61/499,047 2011-06-20
US201161533098P 2011-09-09 2011-09-09
US201161533123P 2011-09-09 2011-09-09
US61/533,098 2011-09-09
US61/533,123 2011-09-09
US201161579544P 2011-12-22 2011-12-22
US61/579,544 2011-12-22
PCT/US2012/032426 WO2012138927A2 (en) 2011-04-05 2012-04-05 Method for the generation of compact tale-nucleases and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017248447A Division AU2017248447B2 (en) 2011-04-05 2017-10-17 Method for the generation of compact tale-nucleases and uses thereof

Publications (2)

Publication Number Publication Date
AU2012240110A1 AU2012240110A1 (en) 2013-10-31
AU2012240110B2 true AU2012240110B2 (en) 2017-08-03

Family

ID=45976522

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012240110A Active AU2012240110B2 (en) 2011-04-05 2012-04-05 Method for the generation of compact tale-nucleases and uses thereof
AU2017248447A Active AU2017248447B2 (en) 2011-04-05 2017-10-17 Method for the generation of compact tale-nucleases and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017248447A Active AU2017248447B2 (en) 2011-04-05 2017-10-17 Method for the generation of compact tale-nucleases and uses thereof

Country Status (13)

Country Link
US (5) US20140115726A1 (https=)
EP (3) EP2694089B1 (https=)
JP (3) JP5996630B2 (https=)
KR (1) KR101982360B1 (https=)
CN (1) CN103608027B (https=)
AU (2) AU2012240110B2 (https=)
CA (2) CA3111953C (https=)
DK (1) DK2694091T3 (https=)
ES (1) ES2728436T3 (https=)
HK (1) HK1253952A1 (https=)
IL (1) IL228747B (https=)
SG (2) SG10201602651YA (https=)
WO (2) WO2012138939A1 (https=)

Families Citing this family (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028347A2 (en) 2008-09-05 2010-03-11 President & Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
AU2011265733B2 (en) * 2010-06-14 2014-04-17 Iowa State University Research Foundation, Inc. Nuclease activity of TAL effector and Foki fusion protein
CA2825370A1 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
JP6214530B2 (ja) 2011-07-15 2017-10-18 ザ ジェネラル ホスピタル コーポレイション 転写活性化因子様エフェクターの組立て方法
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013043638A1 (en) * 2011-09-23 2013-03-28 Iowa State University Research Foundation, Inc. Monomer architecture of tal nuclease or zinc finger nuclease for dna modification
WO2013068845A2 (en) 2011-11-07 2013-05-16 The University Of Western Ontario Endonuclease for genome editing
HK1200871A1 (en) 2011-11-16 2015-08-14 Sangamo Therapeutics, Inc. Modified dna-binding proteins and uses thereof
WO2013101877A2 (en) 2011-12-29 2013-07-04 Iowa State University Research Foundation, Inc. Genetically modified plants with resistance to xanthomonas and other bacterial plant pathogens
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
DK2825190T3 (en) * 2012-03-15 2017-02-27 Cellectis REPEAT VARIABLE DIRESTS FOR TARGETING NUCLEOTIDES
EP2839013B1 (en) * 2012-04-18 2020-08-26 The Board of Trustees of the Leland Stanford Junior University Non-disruptive gene targeting
CN104245940A (zh) 2012-04-23 2014-12-24 拜尔作物科学公司 植物中的靶向基因组工程
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
WO2013182910A2 (en) * 2012-06-05 2013-12-12 Cellectis New transcription activator-like effector (tale) fusion protein
US20150225734A1 (en) 2012-06-19 2015-08-13 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
US9091827B2 (en) 2012-07-09 2015-07-28 Luxtera, Inc. Method and system for grating couplers incorporating perturbed waveguides
MX367730B (es) 2012-09-04 2019-09-04 Cellectis Receptor de antigeno quimerico multi-cadena y usos del mismo.
CN103668470B (zh) * 2012-09-12 2015-07-29 上海斯丹赛生物技术有限公司 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
EP3789405A1 (en) 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
CA2890160A1 (en) 2012-10-31 2014-05-08 Cellectis Coupling herbicide resistance with targeted insertion of transgenes in plants
KR102121086B1 (ko) * 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
CA2891510C (en) 2012-11-16 2022-10-18 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
CN105121649A (zh) 2012-11-16 2015-12-02 赛莱蒂克斯公司 靶向修饰藻基因组的方法
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
WO2014102688A1 (en) 2012-12-27 2014-07-03 Cellectis New design matrix for improvement of homology-directed gene targeting
EP2951295B1 (en) 2013-02-01 2018-08-01 Cellectis Tevi chimeric endonucleases and their preferential cleavage sites
EP2954042B1 (en) 2013-02-07 2017-12-06 The General Hospital Corporation Tale transcriptional activators
US20150353885A1 (en) 2013-02-21 2015-12-10 Cellectis Method to counter-select cells or organisms by linking loci to nuclease components
RU2662932C2 (ru) * 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
CA2908403A1 (en) 2013-04-02 2014-10-09 Bayer Cropscience Nv Targeted genome engineering in eukaryotes
WO2014169810A1 (zh) * 2013-04-16 2014-10-23 深圳华大基因科技服务有限公司 分离的寡核苷酸及其用途
FI2997141T3 (fi) 2013-05-13 2022-12-15 CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
CA2913871C (en) * 2013-05-31 2021-07-13 Cellectis A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof
ES2716867T3 (es) * 2013-05-31 2019-06-17 Cellectis Sa Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma
JP2016521561A (ja) * 2013-06-14 2016-07-25 セレクティス 植物における非トランスジェニックのゲノム編集のための方法
JP2016523093A (ja) * 2013-06-25 2016-08-08 セレクティスＣｅｌｌｅｃｔｉｓ バイオ燃料生産のための改変された珪藻
FR3008106A1 (fr) * 2013-07-05 2015-01-09 Agronomique Inst Nat Rech Methode d'induction d'une recombinaison meiotique ciblee
US10782479B2 (en) 2013-07-08 2020-09-22 Luxtera Llc Method and system for mode converters for grating couplers
US10006011B2 (en) 2013-08-09 2018-06-26 Hiroshima University Polypeptide containing DNA-binding domain
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
EP3049116B1 (en) * 2013-09-23 2019-01-02 Rensselaer Polytechnic Institute Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
US9476884B2 (en) 2013-10-04 2016-10-25 University Of Massachusetts Hybridization- independent labeling of repetitive DNA sequence in human chromosomes
CA2927965A1 (en) * 2013-10-25 2015-04-30 Cellectis Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
WO2015121454A1 (en) 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
JP6681837B2 (ja) 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
PL3119807T3 (pl) 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
BR112016019940A2 (pt) 2014-03-21 2017-10-24 Univ Leland Stanford Junior edição de genoma sem nucleases
JP2017513472A (ja) 2014-04-11 2017-06-01 セレクティスＣｅｌｌｅｃｔｉｓ アルギニンおよび／またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
US20170107541A1 (en) * 2014-06-17 2017-04-20 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
WO2016016344A1 (en) 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
EP3189073B2 (en) 2014-09-04 2025-06-11 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US20160244784A1 (en) * 2015-02-15 2016-08-25 Massachusetts Institute Of Technology Population-Hastened Assembly Genetic Engineering
JP2018509148A (ja) 2015-03-11 2018-04-05 セレクティスＣｅｌｌｅｃｔｉｓ 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
ES2905181T3 (es) * 2015-05-01 2022-04-07 Prec Biosciences Inc Deleción precisa de secuencias cromosómicas in vivo
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
US11473082B2 (en) 2015-06-17 2022-10-18 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
JP7033453B2 (ja) 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
CN104962523B (zh) 2015-08-07 2018-05-25 苏州大学 一种测定非同源末端连接修复活性的方法
WO2017025323A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
WO2017079428A1 (en) 2015-11-04 2017-05-11 President And Fellows Of Harvard College Site specific germline modification
WO2017178585A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
WO2017178586A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11293033B2 (en) 2016-05-18 2022-04-05 Amyris, Inc. Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
PL3464333T3 (pl) 2016-05-26 2024-09-30 Nunhems B.V. Rośliny wytwarzające bezpestkowe owoce
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
MX2019001956A (es) 2016-08-17 2019-09-04 Monsanto Technology Llc Metodos y composiciones para plantas de estatura corta a traves de la manipulacion del metabolismo de giberelina para aumentar el rendimiento cosechable.
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
DK3523326T3 (da) 2016-10-04 2020-08-03 Prec Biosciences Inc Samstimulerende domæner til anvendelse i genetisk modificerede celler
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018091971A1 (en) * 2016-11-15 2018-05-24 Genomic Vision Method for the monitoring of modified nucleases induced-gene editing events by molecular combing
AU2017378427A1 (en) 2016-12-14 2019-06-20 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018162702A1 (en) 2017-03-10 2018-09-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nuclease fusions for enhancing genome editing by homology-directed transgene integration
JP6901293B2 (ja) * 2017-03-15 2021-07-14 株式会社三共 遊技用装置
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
AU2018246377B2 (en) 2017-03-31 2025-01-30 Cellectis Sa Universal anti-CD22 chimeric antigen receptor engineered immune cells
EP4029943A1 (en) 2017-05-08 2022-07-20 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
MA48797A (fr) 2017-05-25 2020-04-08 Bluebird Bio Inc Variants de l'endonucléase cblb , compositions et procédés d'utilisation
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US12060553B2 (en) 2017-08-25 2024-08-13 President And Fellows Of Harvard College Evolution of BoNT peptidases
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
WO2019060631A1 (en) * 2017-09-20 2019-03-28 Helix Nanotechnologies, Inc. EXPRESSION SYSTEMS THAT FACILITATE THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE
EP4269560A3 (en) 2017-10-03 2024-01-17 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
DK3501268T3 (da) 2017-12-22 2021-11-08 Kws Saat Se & Co Kgaa Regenerering af planter i tilstedeværelse af histondeacetylase hæmmere
EP3508581A1 (en) 2018-01-03 2019-07-10 Kws Saat Se Regeneration of genetically modified plants
AU2019207409B2 (en) 2018-01-12 2023-02-23 Basf Se Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
US20230158070A1 (en) 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CA3090007A1 (en) 2018-02-15 2019-08-22 Monsanto Technology Llc Improved methods for hybrid corn seed production
AR114124A1 (es) 2018-02-15 2020-07-22 Monsanto Technology Llc Composiciones y métodos para mejorar el rendimiento de cultivos a través de apilamiento de rasgos
WO2019161149A1 (en) 2018-02-15 2019-08-22 Monsanto Technology Llc Methods and compositions for increasing harvestable yield via editing ga20 oxidase genes to generate short stature plants
EP3545756A1 (en) 2018-03-28 2019-10-02 KWS SAAT SE & Co. KGaA Regeneration of plants in the presence of inhibitors of the histone methyltransferase ezh2
MA52207A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3234120A1 (en) 2018-05-02 2019-11-07 Cellectis Engineering wheat with increased dietary fiber
DK3567111T3 (da) 2018-05-09 2025-10-13 Kws Saat Se & Co Kgaa Gen til resistens over for et patogen af slægten heterodera
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
DK3806903T5 (da) 2018-06-14 2024-08-19 2Seventy Bio Inc Cd79a kimæriske antigenreceptorer
CN112585269B (zh) 2018-06-15 2025-01-07 科沃施种子欧洲股份两合公司 改善植物中基因组工程化和再生的方法ii
EP3806619A1 (en) 2018-06-15 2021-04-21 Nunhems B.V. Seedless watermelon plants comprising modifications in an abc transporter gene
WO2019238909A1 (en) 2018-06-15 2019-12-19 KWS SAAT SE & Co. KGaA Methods for improving genome engineering and regeneration in plant
AU2019285082B2 (en) 2018-06-15 2024-09-19 KWS SAAT SE & Co. KGaA Methods for enhancing genome engineering efficiency
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP3623379A1 (en) 2018-09-11 2020-03-18 KWS SAAT SE & Co. KGaA Beet necrotic yellow vein virus (bnyvv)-resistance modifying gene
WO2020072059A1 (en) * 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP7854297B2 (ja) 2018-11-05 2026-05-01 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
US12274205B2 (en) 2018-12-12 2025-04-15 Monsanto Technology Llc Delayed harvest of short stature corn plants
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020132659A1 (en) 2018-12-21 2020-06-25 Precision Biosciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US12606839B2 (en) 2019-01-29 2026-04-21 The University Of Warwick Methods for enhancing genome engineering efficiency
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3708651A1 (en) 2019-03-12 2020-09-16 KWS SAAT SE & Co. KGaA Improving plant regeneration
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3947667A4 (en) * 2019-03-26 2022-12-28 Encodia, Inc. MODIFIED CLEAVASE, USES THEREOF AND RELATED KITS
US11427814B2 (en) 2019-03-26 2022-08-30 Encodia, Inc. Modified cleavases, uses thereof and related kits
KR102691932B1 (ko) 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
EP3947646A1 (en) 2019-04-05 2022-02-09 Precision BioSciences, Inc. Methods of preparing populations of genetically-modified immune cells
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CA3136742A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
EP3966334A1 (en) 2019-05-10 2022-03-16 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP3757219A1 (en) 2019-06-28 2020-12-30 KWS SAAT SE & Co. KGaA Enhanced plant regeneration and transformation by using grf1 booster gene
CA3145425A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US20220273715A1 (en) 2019-07-25 2022-09-01 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US20220267732A1 (en) 2019-08-01 2022-08-25 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
CA3148179A1 (en) 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
CN114729382A (zh) 2019-09-12 2022-07-08 巴斯夫欧洲公司 增强植物中基因表达的调节性核酸分子
WO2021069387A1 (en) 2019-10-07 2021-04-15 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CA3146672A1 (en) * 2019-10-11 2021-04-15 Thaquoris PITT Increase in corn transformation efficacy by the n-terminus of a tale
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20220411479A1 (en) 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
JP7753203B2 (ja) 2019-11-12 2025-10-14 カー・ヴェー・エス ザート エス・エー ウント コー． カー・ゲー・アー・アー ヘテロデラ属の病原体に対する耐性遺伝子
CA3159805A1 (en) 2019-12-03 2021-06-10 Frank Meulewaeter Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2021113543A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
WO2021146222A1 (en) 2020-01-13 2021-07-22 Sana Biotechnology, Inc. Modification of blood type antigens
KR20220142433A (ko) 2020-01-17 2022-10-21 사나 바이오테크놀로지, 인크. 유전자 발현 조절용 안전 스위치
WO2021158915A1 (en) 2020-02-06 2021-08-12 Precision Biosciences, Inc. Recombinant adeno-associated virus compositions and methods for producing and using the same
US12473563B2 (en) 2020-02-28 2025-11-18 KWS SAAT SE & Co. KGaA Immature inflorescence meristem editing
KR20220158046A (ko) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. 신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
US20230263121A1 (en) 2020-03-31 2023-08-24 Elo Life Systems Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
WO2021231549A2 (en) * 2020-05-12 2021-11-18 Factor Bioscience Inc. Engineered gene-editing proteins
CN115835873A (zh) 2020-05-13 2023-03-21 朱诺治疗学股份有限公司 用于产生表达重组受体的供体分批细胞的方法
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
EP4192875A1 (en) 2020-08-10 2023-06-14 Precision BioSciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
WO2022036150A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
US20240060079A1 (en) 2020-10-23 2024-02-22 Elo Life Systems Methods for producing vanilla plants with improved flavor and agronomic production
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
US20220162632A1 (en) 2020-11-23 2022-05-26 Monsanto Technology Llc Delayed harvest of short stature corn plants
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
EP4019638A1 (en) 2020-12-22 2022-06-29 KWS SAAT SE & Co. KGaA Promoting regeneration and transformation in beta vulgaris
EP4019639A1 (en) 2020-12-22 2022-06-29 KWS SAAT SE & Co. KGaA Promoting regeneration and transformation in beta vulgaris
JP2024501971A (ja) 2020-12-31 2024-01-17 サナ バイオテクノロジー，インコーポレイテッド Ｃａｒ－ｔ活性を調節するための方法及び組成物
US20250127811A1 (en) 2021-01-28 2025-04-24 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US20240191191A1 (en) 2021-03-19 2024-06-13 Iovance Biotherapeutics, Inc. Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
CA3213080A1 (en) 2021-03-23 2022-09-29 Krit RITTHIPICHAI Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US20240141311A1 (en) 2021-04-22 2024-05-02 North Carolina State University Compositions and methods for generating male sterile plants
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
US20240226164A1 (en) 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
EP4373270A2 (en) 2021-07-22 2024-05-29 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
EP4384598A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
US20240358761A1 (en) 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
WO2023039488A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
IL312244A (en) 2021-10-19 2024-06-01 Prec Biosciences Inc Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
CN113980141B (zh) * 2021-10-27 2022-11-29 湖北大学 基于大肠杆菌素e家族dna酶的蛋白质复合物及其在人工蛋白支架中的应用
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US12577624B2 (en) 2021-11-02 2026-03-17 Monsanto Technology Llc Transgenic corn event ZM_BCS216090 and methods for detection and uses thereof
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
EP4430206A1 (en) 2021-11-10 2024-09-18 Encodia, Inc. Methods for barcoding macromolecules in individual cells
WO2023091910A1 (en) 2021-11-16 2023-05-25 Precision Biosciences, Inc. Methods for cancer immunotherapy
EP4437091A1 (en) 2021-11-23 2024-10-02 Cellectis SA New tale protein scaffolds with improved on-target/off-target activity ratios
US20250064986A1 (en) 2022-01-07 2025-02-27 Precision Biosciences, Inc. Optimized polynucleotides for protein expression
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
EP4479416A1 (en) 2022-02-17 2024-12-25 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
CA3251533A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
EP4583889A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
EP4605524A1 (en) 2022-10-20 2025-08-27 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2024097313A1 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Methods for producing t cell therapy products
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
JP2025539816A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
JP2025539712A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 遺伝子編集されたｔ細胞の増殖能を評価するための方法
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
JP2026504491A (ja) 2023-02-03 2026-02-05 ツェー３エス２ ゲーエムベーハー 操作された免疫細胞の非ウイルス的製造のための方法
WO2024216118A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
WO2024216116A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
EP4716541A2 (en) 2023-05-22 2026-04-01 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
CN117344048A (zh) * 2023-09-28 2024-01-05 江苏省农业科学院 检测无毒基因Avr-Pik的RPA-LFD引物探针组、试剂盒及其应用
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
CN117821413B (zh) * 2023-12-15 2024-12-27 湖北大学 一种高进行性Pfu DNA聚合酶及其制备方法和应用
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis
WO2025181336A1 (en) 2024-03-01 2025-09-04 Cellectis Sa Compositions and methods for hbb-editing in hspc
WO2025212519A1 (en) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2026046724A1 (en) 2024-08-30 2026-03-05 Cellectis Sa Tale protein scaffolds involving fusions of monopartite and bipartite nls
WO2026083329A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5006333A (en) 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
WO2007034262A1 (en) 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
EP1863909B2 (en) 2005-03-15 2014-09-10 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
US20100146651A1 (en) 2006-11-14 2010-06-10 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
WO2008093152A1 (en) 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
WO2008102199A1 (en) 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
WO2008149176A1 (en) 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
WO2009013559A1 (en) 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
EP2206723A1 (en) * 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US8586526B2 (en) * 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN102762726A (zh) * 2009-11-27 2012-10-31 巴斯夫植物科学有限公司 嵌合内切核酸酶及其用途
WO2011072246A2 (en) * 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
WO2011104382A1 (en) * 2010-02-26 2011-09-01 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
US20130337454A1 (en) * 2010-10-27 2013-12-19 Philippe Duchateau Method for increasing the efficiency of double-strand break-induced mutagenesis
US9499592B2 (en) * 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
US8673557B2 (en) * 2011-02-28 2014-03-18 Seattle Children's Research Institute Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
ES2716867T3 (es) * 2013-05-31 2019-06-17 Cellectis Sa Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU QINGQING ET AL: "Distance determination by GIY-YIG intron endonucleases: discrimination between repression and cleavage functions.", NUCLEIC ACIDS RESEARCH, vol. 34, no. 6, 2006, pages 1755-1764. *
MILLER JEFFREY C ET AL: "A TALE nuclease architecture for efficient genome editing.", NATURE BIOTECHNOLOGY, vol. 29, no. 2, February 2011, pages 143-148. *

Also Published As

Publication number Publication date
CN103608027B (zh) 2016-01-20
AU2017248447B2 (en) 2019-01-24
CA2832534A1 (en) 2012-10-11
CA3111953A1 (en) 2012-10-11
ES2728436T3 (es) 2019-10-24
JP2017018125A (ja) 2017-01-26
KR101982360B1 (ko) 2019-05-24
HK1253952A1 (en) 2019-07-05
WO2012138927A3 (en) 2013-04-25
IL228747B (en) 2020-04-30
CN103608027A (zh) 2014-02-26
EP2694089B1 (en) 2024-06-05
SG10201602651YA (en) 2016-05-30
US20160298098A1 (en) 2016-10-13
EP2694089A1 (en) 2014-02-12
JP2014511698A (ja) 2014-05-19
IL228747A0 (en) 2013-12-31
EP3320910A1 (en) 2018-05-16
CA2832534C (en) 2022-01-04
JP2019010119A (ja) 2019-01-24
US20130117869A1 (en) 2013-05-09
US20190316100A1 (en) 2019-10-17
EP2694091A2 (en) 2014-02-12
JP6839691B2 (ja) 2021-03-10
WO2012138927A2 (en) 2012-10-11
US20140115726A1 (en) 2014-04-24
KR20140050602A (ko) 2014-04-29
SG194115A1 (en) 2013-11-29
CA3111953C (en) 2023-10-24
AU2017248447A1 (en) 2017-11-02
JP6695239B2 (ja) 2020-05-20
EP2694091B1 (en) 2019-03-13
US9315788B2 (en) 2016-04-19
US11136566B2 (en) 2021-10-05
JP5996630B2 (ja) 2016-09-21
WO2012138939A1 (en) 2012-10-11
US20220010292A1 (en) 2022-01-13
US11198856B2 (en) 2021-12-14
AU2012240110A1 (en) 2013-10-31
DK2694091T3 (da) 2019-06-03

Similar Documents

Publication Publication Date Title
AU2017248447B2 (en) Method for the generation of compact tale-nucleases and uses thereof
EP2633040B1 (en) Method for increasing the efficiency of double-strand break-induced mutagenesis
US9540623B2 (en) Method for increasing the efficiency of double-strand-break induced mutagenesis
US11220683B2 (en) Method to overcome DNA chemical modifications sensitivity of engineered TALE DNA binding domains
EP2951295B1 (en) Tevi chimeric endonucleases and their preferential cleavage sites
WO2012138901A1 (en) Method for enhancing rare-cutting endonuclease efficiency and uses thereof
HK1192709A (en) Method for the generation of compact tale-nucleases and uses thereof
HK1192709B (en) Method for the generation of compact tale-nucleases and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)